Hemab Therapeutics Holdings, Inc.’s Quiet Period Will Expire on June 10th (NASDAQ:COAG)

Hemab Therapeutics’ (NASDAQ:COAG) quiet period will end on Wednesday, June 10th. Hemab Therapeutics had issued 16,750,000 shares in its IPO on May 1st. The total size of the offering was $301,500,000 based on an initial share price of $18.00. During Hemab Therapeutics’ quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Wall Street Analysts Forecast Growth

COAG has been the subject of a number of research reports. Wedbush initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $42.00 target price for the company. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 target price for the company. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price for the company. Evercore initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price for the company. Finally, Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.75.

Hemab Therapeutics Stock Performance

Shares of NASDAQ COAG opened at $27.47 on Wednesday. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. acquired 3,802 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average price of $24.97 per share, with a total value of $94,935.94. Following the purchase, the insider owned 6,375,972 shares in the company, valued at approximately $159,208,020.84. The trade was a 0.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have bought 2,902,872 shares of company stock worth $53,769,784.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.